Comparison of diabetes‐associated secondary healthcare utilization between alternative oral antihyperglycaemic dual therapy combinations with metformin in patients with type 2 diabetes: an observational cohort study

To compare diabetes‐associated secondary healthcare utilization in patients with type 2 diabetes (T2DM) prescribed sulphonylureas (SUs) versus other oral antihyperglycaemic agents (OHAs) as an add‐on to metformin monotherapy (metformin + SU vs metformin + OHA).

[1]  A. Morris,et al.  Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. , 2003, Diabetes care.

[2]  Arleen F. Brown,et al.  Socioeconomic position and health among persons with diabetes mellitus: a conceptual framework and review of the literature. , 2004, Epidemiologic reviews.

[3]  J. Robins,et al.  Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. , 2006, American journal of epidemiology.

[4]  A. Morris,et al.  Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin , 2006, Diabetologia.

[5]  V. Fonseca.  Defining and Characterizing the Progression of Type 2 Diabetes , 2009, Diabetes Care.

[6]  P. Elliott,et al.  Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database , 2009, BMJ : British Medical Journal.

[7]  P. Rose,et al.  Validity of diagnostic coding within the General Practice Research Database: a systematic review. , 2010, The British journal of general practice : the journal of the Royal College of General Practitioners.

[8]  J. Carpenter,et al.  Issues in multiple imputation of missing data for large general practice clinical databases , 2010, Pharmacoepidemiology and drug safety.

[9]  A. Vaag,et al.  Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. , 2011, European heart journal.

[10]  S. Heller,et al.  Hypoglycemia and Cardiovascular Risks , 2011, Diabetes Care.

[11]  David M. Smith,et al.  Evidence Linking Hypoglycemic Events to an Increased Risk of Acute Cardiovascular Events in Patients With Type 2 Diabetes , 2011, Diabetes Care.

[12]  B. Wells,et al.  Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis , 2012, Diabetes, obesity & metabolism.

[13]  F. Zhao,et al.  COST-UTILITY ANALYSIS OF LIRAGLUTIDE VERSUS GLIMEPIRIDE AS ADD-ON TO METFORMIN IN TYPE 2 DIABETES PATIENTS IN CHINA , 2012, International Journal of Technology Assessment in Health Care.

[14]  P. McEwan,et al.  Cost Effectiveness of Saxagliptin and Metformin versus Sulfonylurea and Metformin in the Treatment of Type 2 Diabetes Mellitus in Germany , 2012, Clinical Drug Investigation.

[15]  M. Evans,et al.  What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. , 2012, The Journal of clinical endocrinology and metabolism.

[16]  W. Bennett,et al.  Table of Contents AHRQ ’ s Comparative Effectiveness Research on Oral Medications for Type 2 Diabetes : A Summary of the Key Findings , 2012 .

[17]  M J Davies,et al.  Article: Health Economics , 2022 .

[18]  S. Engel,et al.  Sulphonylureas and risk of cardiovascular disease: systematic review and meta‐analysis , 2013, Diabetic medicine : a journal of the British Diabetic Association.

[19]  M. Monami,et al.  Cardiovascular safety of sulfonylureas: a meta‐analysis of randomized clinical trials , 2013, Diabetes, obesity & metabolism.

[20]  W. Rathmann,et al.  Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase‐4 inhibitors and sulphonylureas: a primary care database analysis , 2013, Diabetes, obesity & metabolism.

[21]  C. Currie,et al.  Combination therapy with metformin plus sulphonylureas versus metformin plus DPP‐4 inhibitors: association with major adverse cardiovascular events and all‐cause mortality , 2014, Diabetes, obesity & metabolism.

[22]  C. Currie,et al.  Association between first‐line monotherapy with sulphonylurea versus metformin and risk of all‐cause mortality and cardiovascular events: a retrospective, observational study , 2014, Diabetes, obesity & metabolism.

[23]  Natalia Beloff,et al.  Exploiting the potential of large databases of electronic health records for research using rapid search algorithms and an intuitive query interface , 2013, J. Am. Medical Informatics Assoc..

[24]  Jerome P. Reiter,et al.  A comparison of two methods of estimating propensity scores after multiple imputation , 2016, Statistical methods in medical research.